1757O Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients

Abstract

Tebentafusp (tebe), an investigational TCR–anti-CD3 bispecific fusion protein that targets gp100 and activates T cells, has shown OS benefit in 1st line mUM. OS was improved in patients (pts) regardless of RECISTv1.1 best response, suggesting better surrogate efficacy endpoints are needed.